The US Department of Health and Human Services has awarded $132.5 million to 3 pharmaceutical companies for the advanced development of H5N1 influenza vaccines using an adjuvantan immune system booster. The government has given the companies the task of developing bird-flu vaccines using adjuvants, which increase the body's immune response. Less of this type of vaccine should be required for protection.
The agency awarded $54.8 million to Novartis, $63.3 million to GlaxoSmith- Kline, and $14.4 million to Iomai of Maryland. Under the contracts, each company will increase its capacity to producewithin 6 months after the start of an influenza pandemiceither 150 million doses of an adjuvant-based pandemic influenza vaccine or sufficient adjuvant for 150 million doses of a pandemic influenza vaccine.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs